

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Transfusion: the assessment for and management of transfusion

List of modelling questions

Review question(s) by scope area	What is the clinical and cost-effectiveness of using alternatives to blood transfusion (cell salvage or tranexamic acid) alone or in combination with one another to reduce blood transfusion requirements?
Population	Adult surgical patients at moderate or high risk of bleeding. Subgroup analyses by baseline risk of bleeding: <ul style="list-style-type: none"> • Moderate risk (0.5-1 litre) • High risk (>1 litre)
Interventions and comparators considered for inclusion	Comparators for the high risk of bleeding subgroup: <ol style="list-style-type: none"> 1. Standard treatment (no tranexamic acid or cell salvage) 2. Tranexamic acid 3. Intra-operative cell salvage 4. Post-operative cell salvage 5. Tranexamic acid + intra-operative cell salvage Comparators for the moderate risk of bleeding subgroup: <ol style="list-style-type: none"> 1. Standard treatment (no tranexamic acid or cell salvage) 2. Tranexamic acid 3. Post-operative cell salvage 4. Intra-operative cell salvage + post-operative cell salvage
Perspective	Lifetime
Outcomes	QALYs
Type of analysis	CUA
Issues to note	None